Information for investors

During the ongoing IPO process Cytovac has attracted significant institutional demand, but the general biotech IPO-sentiment has not been considered favorable enough at this point in time to execute an IPO. With advice from Vator Securities, Cytovac’s board and management has therefore decided to complete a private financing round including institutional investors and other investor opportunities.

Cytovac plans to execute on the IPO process post the readout of progression free survival data in the phase II glioblastoma trial expected during summer 2020.

Cytovac’s largest shareholders, management and board continues to support the company in its future positive development.

Cytovac plans to close the first round of private placement within the next few weeks.